{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:25:48Z","timestamp":1787865948605,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011697","name":"R\u00e9gion Bretagne","doi-asserted-by":"publisher","award":["R\u00e9gion Bretagne"],"award-info":[{"award-number":["R\u00e9gion Bretagne"]}],"id":[{"id":"10.13039\/501100011697","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eugene Marquis Comprehensive Cancer Center","award":["COGEDOR"],"award-info":[{"award-number":["COGEDOR"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-026-07803-8","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:18:59Z","timestamp":1771287539000},"page":"3915-3924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients"],"prefix":"10.1007","volume":"53","author":[{"given":"Itzel","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helo\u00efse","family":"Bourien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan","family":"Morel-Corlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Peinoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Le Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4765-6683","authenticated-orcid":false,"given":"Yan","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-2863","authenticated-orcid":false,"given":"Etienne","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-1479","authenticated-orcid":false,"given":"Oscar","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"7803_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/COC.0b013e3181df0a50","volume":"34","author":"B Sangro","year":"2011","unstructured":"Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol. 2011;34:422\u201331. https:\/\/doi.org\/10.1097\/COC.0b013e3181df0a50.","journal-title":"Am J Clin Oncol"},{"key":"7803_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E, Vogel A, Cervantes A, Chau I, Daniele B, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014.","journal-title":"Ann Oncol"},{"key":"7803_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.10.020","author":"M Reig","year":"2025","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020. S0168827825025711.","journal-title":"J Hepatol"},{"key":"7803_CR4","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(17)30683-6.","journal-title":"Lancet Oncol"},{"key":"7803_CR5","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.006.","journal-title":"J Hepatol"},{"key":"7803_CR6","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913\u201321. https:\/\/doi.org\/10.1200\/JCO.2017.76.0892.","journal-title":"J Clin Oncol"},{"key":"7803_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30024-X","volume":"19","author":"E Garin","year":"2018","unstructured":"Garin E, Rolland Y, Campillo-Gimenez B, Edeline J. Negative phase 3 study of (90)Y microspheres versus sorafenib in HCC. Lancet Oncol. 2018;19:e70. https:\/\/doi.org\/10.1016\/S1470-2045(18)30024-X.","journal-title":"Lancet Oncol"},{"key":"7803_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65:264\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266211.","journal-title":"J Nucl Med"},{"key":"7803_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7803_CR10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/hep.26191","volume":"57","author":"B Gil-Alzugaray","year":"2013","unstructured":"Gil-Alzugaray B, Chopitea A, I\u00f1arrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57:1078\u201387. https:\/\/doi.org\/10.1002\/hep.26191.","journal-title":"Hepatology"},{"key":"7803_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153794","volume":"13","author":"C Lescure","year":"2021","unstructured":"Lescure C, Estrade F, Pedrono M, Campillo-Gimenez B, Le Sourd S, Pracht M, et al. ALBI score is a strong predictor of toxicity following SIRT for hepatocellular carcinoma. Cancers. 2021;13:3794. https:\/\/doi.org\/10.3390\/cancers13153794.","journal-title":"Cancers"},{"key":"7803_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215427","volume":"13","author":"DJ Van Doorn","year":"2021","unstructured":"Van Doorn DJ, Hendriks P, Burgmans MC, Rietbergen DDD, Coenraad MJ, Van Delden OM, et al. Liver decompensation as late complication in HCC patients with long-term response following selective internal radiation therapy. Cancers. 2021;13:5427. https:\/\/doi.org\/10.3390\/cancers13215427.","journal-title":"Cancers"},{"key":"7803_CR13","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7803_CR14","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","volume":"47","author":"C Chiesa","year":"2020","unstructured":"Chiesa C, Mira M, Bhoori S, Bormolini G, Maccauro M, Spreafico C, et al. Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47:3018\u201332. https:\/\/doi.org\/10.1007\/s00259-020-04845-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7803_CR15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/cncr.23339","volume":"112","author":"B Sangro","year":"2008","unstructured":"Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538\u201346. https:\/\/doi.org\/10.1002\/cncr.23339.","journal-title":"Cancer"},{"key":"7803_CR16","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/hep.26191","volume":"57","author":"B Gil-Alzugaray","year":"2013","unstructured":"Gil-Alzugaray B, Chopitea A, I\u00f1arrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57:1078\u201387.","journal-title":"Hepatology"},{"key":"7803_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"7803_CR18","first-page":"419","volume":"8","author":"AKM Rahman","year":"2019","unstructured":"Rahman AKM, Shamrat FM, Tasnim Z, Roy J. A comparative study on liver disease prediction using supervised machine learning algorithms. Int J Sci Technol Res. 2019;8:419\u201322.","journal-title":"Int J Sci Technol Res"},{"key":"7803_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61151-x","volume":"14","author":"S Kasim","year":"2024","unstructured":"Kasim S, Amir Rudin PNF, Malek S, Ibrahim KS, Wan Ahmad WA, Fong AYY, et al. Ensemble machine learning for predicting in-hospital mortality in Asian women with ST-elevation myocardial infarction (STEMI). Sci Rep. 2024;14:12378. https:\/\/doi.org\/10.1038\/s41598-024-61151-x.","journal-title":"Sci Rep"},{"key":"7803_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/frai.2023.1124553","volume":"6","author":"H Blockeel","year":"2023","unstructured":"Blockeel H, Devos L, Fr\u00e9nay B, Nanfack G, Nijssen S. Decision trees: from efficient prediction to responsible AI. Front Artif Intell. 2023;6:1124553. https:\/\/doi.org\/10.3389\/frai.2023.1124553.","journal-title":"Front Artif Intell"},{"key":"7803_CR21","doi-asserted-by":"publisher","DOI":"10.48550\/ARXIV.1702.08608","author":"F Doshi-Velez","year":"2017","unstructured":"Doshi-Velez F, Kim B. Towards a rigorous science of interpretable machine learning. arXiv. 2017. https:\/\/doi.org\/10.48550\/ARXIV.1702.08608.","journal-title":"arXiv"},{"key":"7803_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"7803_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02212-9","volume":"18","author":"A Prayongrat","year":"2023","unstructured":"Prayongrat A, Srimaneekarn N, Thonglert K, Khorprasert C, Amornwichet N, Alisanant P, et al. Correction: machine learning-based normal tissue complication probability model for predicting albumin-bilirubin (ALBI) grade increase in hepatocellular carcinoma patients. Radiat Oncol. 2023;18:53. https:\/\/doi.org\/10.1186\/s13014-023-02212-9.","journal-title":"Radiat Oncol"},{"key":"7803_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.57.9151.","journal-title":"J Clin Oncol"},{"key":"7803_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061557","volume":"12","author":"E Garin","year":"2020","unstructured":"Garin E, Palard X, Rolland Y. Personalised dosimetry in radioembolisation for HCC: impact on clinical outcome and on trial design. Cancers. 2020;12:1557. https:\/\/doi.org\/10.3390\/cancers12061557.","journal-title":"Cancers"},{"key":"7803_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50:328\u201343. https:\/\/doi.org\/10.1007\/s00259-022-05956-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7803_CR27","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10278-022-00762-0","volume":"36","author":"WV Wagstaff","year":"2023","unstructured":"Wagstaff WV, Villalobos A, Gichoya J, Kokabi N. Using deep learning to predict treatment response in patients with hepatocellular carcinoma treated with Y90 radiation segmentectomy. J Digit Imaging. 2023;36:1180\u20138. https:\/\/doi.org\/10.1007\/s10278-022-00762-0.","journal-title":"J Digit Imaging"},{"key":"7803_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jvir.2022.11.004","volume":"34","author":"O \u0130nce","year":"2023","unstructured":"\u0130nce O, \u00d6nder H, Gen\u00e7t\u00fcrk M, Cebeci H, Golzarian J, Young S. Prediction of response of hepatocellular carcinoma to radioembolization: machine learning using preprocedural clinical factors and MR imaging radiomics. J Vasc Interv Radiol. 2023;34:235\u2013e2433. https:\/\/doi.org\/10.1016\/j.jvir.2022.11.004.","journal-title":"J Vasc Interv Radiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07803-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07803-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07803-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:25:58Z","timestamp":1777274758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07803-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7803"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07803-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and approved by the ethics committee of the Centre Eug\u00e8ne Marquis. The methodology respected the French MR-004 methodology for retrospective studies. The patients had the opportunity to express refusal to participate to retrospective studies.YR declares consulting for Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed an inform consent form to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors affirm that all participants of the study were provided with a consent form for publication of the presented data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"JE declares Consulting: MSD, Eisai, BMS, AstraZeneca, Bayer, Roche, Ipsen, Basilea, Merck Serono, Incyte, Servier, Beigene, Taiho, Boston Scientific, Guerbet, Jazz, Captor therapeutics; Research funding (institutional): BMS, Beigene, Boston Scientific, Exeliom biosciences, SUMMIT, AstraZeneca.EG declares consulting for Boston Scientific, and research funding (institutional) from Boston Scientific.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}